Expression Levels News Today

- CDR404 represents a potential paradigm shift in the development of T-cell engagers for solid cancers - Epithelial cancer indications eligible for CDR404 Phase 1 trial include non-small cell lung carcinoma (NSCLC), head & neck squamous cell carcinoma and bladder cancer ZÜRICH, Switzerland, Oct. 23, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. presented findings on tumor target expression and precise patient selection for the upcoming Phase 1 trial of CDR404 (Abstract 200P), a first-of-its-k...

Dublin, Oct. 27, 2022 (GLOBE NEWSWIRE) -- The "Global Protein Expression Market by Type (E.Coli, Mammalian, CHO, HEK 293, Insect, Pichia, Cell-free),...

Exploring the therapeutic mechanism of sacubitril/valsartan in rats with early diabetic nephropathy. Read more

1 1Department of Neurosurgery, The First Affiliated Hospital of Jinan University, Guangzhou City, Guangdong Province 510630, People’s Republic of China; 2Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, People’s Republic of China Correspondence: Xiangyu Wang Department of Neurosurgery, The First Affiliated Hospital of Jinan University, No. 613 West Huangpu Avenue, Tianhe District, Guangzhou City, Guangdong Province 510630, People’s Republi...